# Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma

> **NCT04853329** · PHASE1 · TERMINATED · sponsor: **Conjupro Biotherapeutics, Inc.** · enrollment: 7 (actual)

## Conditions studied

- CD20 Positive Non Hodgkin Lymphoma

## Interventions

- **DRUG:** CPO107

## Key facts

- **NCT ID:** NCT04853329
- **Lead sponsor:** Conjupro Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-13
- **Primary completion:** 2023-01-31
- **Final completion:** 2023-01-31
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04853329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04853329, "Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04853329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*